Peripheral CB1 Receptor Compounds for Metabolic Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CB1 receptor blocking drugs for obesity and metabolic syndrome treatment cause neuropsychiatric side effects, limiting their therapeutic development.
Innovation Solution
Development of peripherally restricted cannabinoid receptor mediating compounds that selectively target CB1 receptors in peripheral tissues, minimizing brain penetration to reduce neuropsychiatric effects while maintaining metabolic benefits, and incorporating secondary therapeutic scaffolds like metformin for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CB1 receptor blocking drugs are used to treat obesity and metabolic syndrome, then metabolic efficacy is improved, but neuropsychiatric side effects occur
Solution Approach 1:
The invention divides the therapeutic effect into two separate components: a CB1 receptor mediating compound for metabolic efficacy and a second therapeutic scaffold (such as metformin for AMPK activation) for addressing insulin resistance and neuropsychiatric side effects. This segmentation allows the CB1 blocker to work peripherally while the second scaffold addresses central effects, resolving the contradiction between metabolic efficacy and neuropsychiatric side effects
Solution Approach 2:
The patent introduces a second therapeutic scaffold as an intermediary agent that works in combination with the CB1 receptor mediating compound. This intermediary (e.g., metformin) activates AMPK to improve insulin resistance and counteract neuropsychiatric side effects, while the CB1 compound maintains its metabolic benefits. The intermediary mediates between the CB1 blocker's metabolic effects and the need to reduce neuropsychiatric side effects
2Reliability
If compounds are designed to block CB1 receptors in brain to treat metabolic syndrome, then metabolic benefits are achieved, but neuropsychiatric side effects increase
Solution Approach 1:
The invention applies local quality by designing the CB1 receptor mediating compound to selectively target peripheral CB1 receptors (in adipose tissue, liver, muscle) while minimizing penetration into the brain. This spatial differentiation allows the compound to exert metabolic benefits in peripheral tissues without causing central neuropsychiatric side effects, resolving the contradiction between metabolic benefits and neuropsychiatric side effects
3Ease of operation
If single-agent CB1 blockers are used, then treatment simplicity is maintained, but therapeutic efficacy is limited
Solution Approach 1:
The patent merges two therapeutic agents into a single compound structure: a CB1 receptor mediating compound linked to a second therapeutic scaffold (such as metformin). This merging creates a dual-action agent that simultaneously blocks CB1 receptors for metabolic benefits and activates AMPK for improved insulin resistance, thereby enhancing overall therapeutic efficacy while maintaining ease of administration as a single oral compound
Data Source
AI summary
A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.